The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits by Szałek, E. et al.
Animal Science Publications Animal Science 
2014 
The influence of the time-of-day administration of the drug on the 
pharmacokinetics of sunitinib in rabbits 
E. Szałek 
Karol Marcinkowski University of Medical Sciences 
A. Karbownik 
Karol Marcinkowski University of Medical Sciences 
K. Sobańska 
Karol Marcinkowski University of Medical Sciences 
W. Połom 
University Clinical Centre, Gdansk 
T. Grabowski 
Polpharma Biologics, Gdansk 
See next page for additional authors 
Follow this and additional works at: https://lib.dr.iastate.edu/ans_pubs 
 Part of the Animal Experimentation and Research Commons, Animal Sciences Commons, and the 
Medicinal Chemistry and Pharmaceutics Commons 
The complete bibliographic information for this item can be found at https://lib.dr.iastate.edu/
ans_pubs/656. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html. 
This Article is brought to you for free and open access by the Animal Science at Iowa State University Digital 
Repository. It has been accepted for inclusion in Animal Science Publications by an authorized administrator of 
Iowa State University Digital Repository. For more information, please contact digirep@iastate.edu. 
The influence of the time-of-day administration of the drug on the 
pharmacokinetics of sunitinib in rabbits 
Abstract 
OBJECTIVES: At present it is known that the adjustment of the anticancer therapy to the circadian 
rhythms in tissues reduces the toxicity of the treatment. Chronotherapy also increases the efficacy of the 
anticancer treatment, which has been proved for many drugs. Sunitinib is a tyrosine kinase inhibitor, 
which is broadly used for the treatment of numerous cancers. The aim of the study was a comparison of 
the concentrations and pharmacokinetics of sunitinib after a single administration to rabbits at 08:00 
(control group) and 20:00. Additionally, the effect of sunitinib on glucose levels was investigated. 
MATERIALS AND METHODS: The research was carried out on two groups of rabbits: I08:00, a group with 
the drug administered at 08:00 (n=8) and II20:00, a group with the drug administered at 20:00 (n=8). The 
rabbits were treated with sunitinib at an oral dose of 25 mg. Plasma concentrations of sunitinib and its 
metabolite (SU12662) were measured with a validated HPLC method with UV detection. 
RESULTS: The comparison of the sunitinib Cmax and AUC0-t in the group with sunitinib administered at 
20:00 with the control group gave the ratios of 2.20 (90% confidence interval (CI) (2.17; 2.22) and 1.64 
(1.61; 1.68), respectively. Statistically significant differences between the groups under analysis were 
revealed for Cmax (p < 0.0001), AUC0-t (p = 0.0079), AUC0-∞ (p = 0.0149), and tmax (p = 0.0085). The 
mean glycemia drop was higher in group I08:00. than in group II20:00 (22.7% vs. 14.3%; p = 0.0622). The 
glycemia values returned to the initial values in 24 h after the administration of the drug in both groups. 
CONCLUSIONS: The research proved a significant influence of the time-of-day administration on the 
pharmacokinetics of sunitinib. 
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Abstract. – OBJECTIVES: At present it is
known that the adjustment of the anticancer
therapy to the circadian rhythms in tissues re-
duces the toxicity of the treatment. Chronother-
apy also increases the efficacy of the anti-
cancer treatment, which has been proved for
many drugs. Sunitinib is a tyrosine kinase in-
hibitor, which is broadly used for the treatment
of numerous cancers. The aim of the study was
a comparison of the concentrations and phar-
macokinetics of sunitinib after a single admin-
istration to rabbits at 08:00 (control group) and
20:00. Additionally, the effect of sunitinib on
glucose levels was investigated.
MATERIALS AND METHODS: The research
was carried out on two groups of rabbits: I08:00,
a group with the drug administered at 08:00
(n=8) and II20:00, a group with the drug adminis-
tered at 20:00 (n=8). The rabbits were treated
with sunitinib at an oral dose of 25 mg. Plasma
concentrations of sunitinib and its metabolite
(SU12662) were measured with a validated
HPLC method with UV detection.
RESULTS: The comparison of the sunitinib Cmax
and AUC0-t in the group with sunitinib adminis-
tered at 20:00 with the control group gave the ra-
tios of 2.20 (90% confidence interval (CI) (2.17;
2.22) and 1.64 (1.61; 1.68), respectively. Statisti-
cally significant differences between the groups
under analysis were revealed for Cmax (p <
0.0001), AUC0-t (p = 0.0079), AUC0-∞ (p = 0.0149),
and tmax (p = 0.0085). The mean glycemia drop
was higher in group I08:00. than in group II20:00
(22.7% vs. 14.3%; p = 0.0622). The glycemia val-
ues returned to the initial values in 24 h after the
administration of the drug in both groups.
CONCLUSIONS: The research proved a sig-
nificant influence of the time-of-day administra-
tion on the pharmacokinetics of sunitinib.
Key Words:
Sunitinib, SU12662, Chronopharmacokinetics, Rab-
bits, Glycaemia.
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Introduction
Daylight is the most significant stimulus regu-
lating the activity of the supraoptic nucleus. To-
gether with the pineal gland it affects the secre-
tion of melatonin. Additional stimuli synchroniz-
ing the circadian rhythm include routine activities
such as activity, sleep and meals. At present it is
known that the adjustment of the anticancer thera-
py to the circadian rhythms in healthy tissues re-
duces the toxicity of the treatment and taking the
circadian rhythms of neoplastic tissues into ac-
count enables treatment at the time of the day
when the largest numbers of them are divided1,2.
It is the most important aim of cancer chronother-
apy. Numerous research findings indicate that if
cytostatics are administered at the time of the day
when the proliferative activity of the cells in a
particular tissue reaches its peak, the damage to
the tissue is the greatest3. Investigating circadian
rhythms in patients suffering from cancer is a
very complex problem, because this group of pa-
tients has been observed to exhibit changes in the
regulations of circadian rhythms4. So far there has
been no chronopharmacokinetic research on tyro-
sine kinase inhibitors (TKI) although they are
gaining more and more indications. Sunitinib is a
representative of this group. 
Sunitinib belongs to the group of molecularly
targeted drugs with indications for the treatment
of advanced and/or metastatic renal cell cancer,
(MRCC), pancreatic neuroendocrine tumours,
(PNET), and imatinib-resistant gastrointestinal
stromal tumours (GIST)5. Sunitinib disrupts cell
signalling by inhibition of selected tyrosine ki-
nases such as the vascular endothelial growth
factor (VEGF), platelet-derived growth factor
2014; 18: 2393-2399
Pharmacokinetics I8:00 II20:00 Gmean ratiob (90% CI)
parametersa (n=8) (n=8) II20:00 vs. I8:00
Sunitinib
AUC0-t (ng×h/mL) 3301.7 ± 1383.9 (41.9) 5128.4 ± 932.9 (18.2) 1.64 (1.61; 1.68)
AUC∞ (ng×h/mL) 3523.1 ± 1443.7 (41.0) 5210.0 ± 935.9 (18.0) 1.56 (1.53; 1.59)
Cmax (ng/mL) 110.7 ± 23.6 (21.3) 240.9 ± 35.3 (14.7) 2.20 (2.17; 2.22)
tmax (h) 8.1 ± 2.2 (26.7) 5.8 ± 1.2 (20.3) -1.0 (-3.15; 1.15)
AUMC0-t (ng×h2/mL) 87254.7 ± 52800.2 (60.5) 101208.6 ± 37519.9 (37.1) 1.25 (1.22; 1.29)
t1/2kel (h) 26.7 ± 9.1 (34.1) 15.6 ± 2.6 (16.4) 0.60 (0.59; 0.61)
Cl (L/h) 8.1 ± 2.8 (34.4) 4.9 ± 0.9 (18.2) 0.64 (0.63; 0.65)
SU12662
AUC0-t (ng×h/mL) 344.6 ± 164.6 (47.8) 505.6 ± 178.2 (35.2) 1.53 (1.49; 1.58)
AUC0-∞ (ng×h/mL) 460.5 ± 160.5 (34.9) 534.0 ± 176.6 (33.1) 1.16 (1.14; 1.18)
Cmax (ng/mL) 10.4 ± 4.9 (46.9) 25.8 ± 10.8 (41.7) 2.49 (2.42; 2.57)
tmax (h) 11.6 ± 5.2 (45.0) 7.6 ± 1.6 (21.0) -3 (-5.05; -0.95)
SU12662/sunitinibc
AUC0-t (ng×h/mL) 0.105 ± 0.033 (31.0) 0.101 ± 0.038 (37.5) 0.93 (0.91; 0.95)
AUC0-∞ (ng×h/mL) 0.138 ± 0.036 (25.9) 0.105 ± 0.039 (36.7) 0.74 (0.73; 0.76)
Cmax (ng/mL) 0.091 ± 0.028 (30.7) 0.106 ± 0.037 (35.5) 1.13 (1.11; 1.16)
Table I. Plasma pharmacokinetic parameters for sunitinib and metabolite (SU12662) following a single oral dose of sunitinib 25 mg.
I8:00, sunitinib at 8:00; II20:00, sunitinib at 20:00; CI, confidence interval; AUC0-t – area under the plasma concentration-time
curve from zero to the time of last measurable concentration; AUC0-∞ – area under the plasma concentration-time curve from
zero to infinity; Cmax – maximum observed plasma concentration; tmax – time to reach maximum concentration; AUMC0-t – area
under the first moment curve; t1/2kel – elimination half-life time; Cl – clearance.
aArithmetic means ± standard deviations are presented with CV (%) in the brackets.
bRatio of geometric means (Gmeans) between groups (%) with the lower and upper bounds of a 90% confidence interval in the
brackets are presented.
cRatio of SU12662/sunitinib exposure.
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(PDGF), stem cell factor (SCF), fms-like tyro-
sine kinase 3 (FLT-3), colony-stimulating factor
(CSF-1R). The drug was released under the com-
mercial name Sutent®. Sunitinib and its main
metabolite SU 12662 are responsible for the anti-
neoplastic activity of the drug6. The drug exhibits
the bioavailability of about 50% after oral admin-
istration7 and it reaches its maximum concentra-
tion in 6-12 h following the administration8. A
daily dose of 50 mg of sunitinib enables the con-
centration of 50-100 ng/mL at steady state,
which determines the pharmacological effect of
the drug9. In vitro investigations proved that both
sunitinib and its active metabolite bind to plasma
proteins to a large extent (95% and 90% respec-
tively)10. The volume of distribution of sunitinib
is 2030 - 2230 L, whereas the volume of distribu-
tion of its metabolite is about 3080 L8,10. Due to
the fact that sunitinib and SU 12662 have long
elimination half-life (40-60 h and 80-110 h re-
spectively), the time necessary to reach the
steady state is 7-14 days for sunitinib and about
14 days for its metabolite11. Sunitinib is chiefly
eliminated with faeces (61%) and to a lesser ex-
tent with urine (16%)8.
The current study was conducted to investigate
the effect of the time of administration of suni-
tinib on its pharmacokinetics (PK) in rabbits, be-
cause there is no available data concerning the
circadian clock of the pharmacokinetics of this
tyrosine kinase inhibitor. Rabbits are not very of-
ten used in chronopharmacokinetic studies, be-
cause of their unimodal or bimodal pattern of ac-
tivity, but feeding conditions can synchronize the
circadian clock of laboratory rabbits12-14.
Materials and Methods
Reagents
Sunitinib and SU12662 were purchased from
LGC Standards (Łomianki, Poland), HPLC grade
E. Szałek, A. Karbownik, K. Sobańska, W. Połom, T. Grabowski, A.Wolc, M. Matuszewski, et al.
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take - the higher activity). The experiments were
conducted in June. All experimental procedures
related to this study were approved by the Local
Ethical Committee for Animal Research.
Evaluation of Sunitinib and SU12662
Pharmacokinetics and Glucose Levels
The animals were fasted on the day of drug
administration. The rabbits were divided into
two groups (8 animals in each): I - receiving
sunitinib in the morning (08:00), and II - receiv-
ing sunitinib in the evening (20:00). Sunitinib
(Sutent® 25 mg) was administered p.o. at the sin-
gle dose of 25 mg15. Blood samples (3 mL) for
sunitinib, SU12662 and glucose assays were col-
lected before and 0.5, 1, 2, 4, 6, 7, 8, 9, 10, 11,
12, 24, 48, 72, 96 hours following drug adminis-
tration. The blood samples were transferred into
heparinized tubes and they were centrifuged at
4000 rpm for 10 min at 4ºC. Next the plasma
was transferred to propylene tubes and stored at
–20°C until analysis. The measurement of suni-
tinib concentration in the blood plasma was
made by means of the HPLC (high-performance
liquid chromatography) method with UV detec-
tion, which was a modification of the method
developed by Faivre et al5. Separation was
achieved by isocratic elution of the mobile
phase, ammonium acetate 20 mM pH 3.4 (ad-
justed with acetic acid) - acetonitrile (60:40,
v/v), at a flow rate of 1.0 mL/min through a
acetonitrile, ammonium acetate and acetic acid
from Sigma-Aldrich (St Louis, MO, USA) and
methanol from Merck (Darmstadt, Germany).
Water used in the mobile phase was deionized,
distilled and filtered through a Millipore system
before use. Sutent® were purchased (batch num-
ber P177H) from Pfizer Trading Polska Sp. z
o.o., Warsaw, Poland.
Animals
Adult New Zealand male rabbits, weighing
2.7-4.5 kg, were used for experiments. All the
rabbits were kept in individual metal cages locat-
ed in the animal laboratory of the University of
Medical Sciences, Department and Unit of Clini-
cal Pharmacy and Biopharmacy. They were accli-
matized for four weeks prior to the experiments
and were maintained under standard conditions
of temperature (23±2°C) and humidity (56-60%)
with an alternating 12 h light/dark cycles to ha-
bituate them to experimental conditions (light-
on: 07:00-19:00 h). New Zealand rabbits were
provided with 100 g of commercial pelleted diet
(Labofeed KB®: Kcynia, Poland) 9.8 MJ/kg
metabolic energy, 16.00% total protein, 0.65%
vitamin P, 15,000 IU vitamin A, 1500 JU vitamin
D3, and 65 mg vitamin E), once daily between
08:00 and 12:00 h, and tap water ad libitum. The
water intake was controlled five times a day
(07:00, 11:00, 15:00, 19:00 and 23:00 h) in order
to measure the activity of rabbits (the greater in-
Figure 1. Sunitinib plasma concentration–time profiles following a single oral dose of sunitinib 25 mg in rabbits after drug
administration in the morning (8:00), and in the evening (20:00) (arithmetic mean with standard deviation). 
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Pharmacokinetics Analysis
Pharmacokinetic parameters were estimated
by non-compartmental methods using validated
software (PhoenixTM WinNonlin® 6.3; Certara
L.P., Saint Louis, MO, USA). The following
pharmacokinetic parameters were calculated for
sunitinib: area under the plasma concentration-
time curve from time zero to infinity (AUC0-∞),
area under the plasma concentration-time curve
from zero to the time of last measurable concen-
tration (AUC0-t), area under the first moment
curve (AUMC0-t), half-life in elimination phase
(t1/2kel), clearance (Cl).
Statistical Analysis
The differences in the values of pharmacokinet-
ic parameters were analysed by means of Student
t-test using PROC TTEST in SAS (SAS Institute
Inc. 2002-2010). The SAS System for Windows
version 9.3. Cary, NC 27513-2414 USA). The dif-
ferences that generated p < 0.05 were considered
statistically significant. The 90% confidence inter-
vals for the ratio of geometric means were con-
structed, except for tmax for which the confidence
intervals were based on the difference of medians.
Results
All the data was expressed as the mean ± stan-
dard deviation (SD). The two analyzed groups
Symmetry® RP-C8 column (250 mm × 4.6 mm,
5.0 mm particle size) (Waters®, Millford, MA,
USA). The column temperature was maintained
at 40°C, the UV detection wavelength was set at
431 nm. The total analysis time for each run was
6 min. The lower limit of quantification (LLOQ)
and limit of detection (LOD) for sunitinib and
SU12662 were 1.0 ng/mL and 0.5 ng/mL, re-
spectively. Intra- and inter-day precision and ac-
curacy of the LLOQ, low quality control (2.5
ng/mL), medium quality control (25.0, 125.0
ng/mL), and high quality control (45.0, 200.0
ng/mL) were well within the acceptable limit of
10% coefficient of variation (CV%) for
SU12662 and sunitinib, respectively. The cali-
bration for sunitinib was linear in the range 1.0-
250.0 ng/mL (r = 0.999), for SU12662 in the
range 1.0-50.0 ng/mL (r = 0.998). 
The blood sugar levels of each of the rabbits
were checked after administration of sunitinib
with an autoanalyzer (AccuCheck Active®) glu-
cose kit. The percentage reduction of the glucose
levels of the rabbits was calculated using the for-
mula:
(V0 – V1)·100reductionglucose = –––––––––––––V0
Where V0 - glucose concentration at zero hour
and Vt - glucose concentration at hour with maxi-
mum reduction.
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Figure 2. Metabolite (SU12662)  plasma concentration–time profiles following a single oral dose of sunitinib 25 mg in rab-
bits after drug administration in the morning (08:00), and in the evening (20:00) (arithmetic mean with standard deviation).
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higher in the morning group and it ranged from
5.5 to 39.0 % for group I08:00 and 7.2 to 20.3% for
group II20:00. The highest drop in glucose concen-
tration was observed about sunitinib tmax (6-12 h).
Discussion
There have been numerous studies evaluating
the influence of biological rhythms on the effica-
cy of drugs and reduction of their adverse reac-
tions16-19. Clinicians are particularly interested in
reduction of the toxicity of anticancer drugs,
which are burdened with numerous serious ad-
verse reactions, and in increasing the efficacy of
therapy with the drugs depending on the time of
the day20-22. Levi et al22 sum up that over 30 anti-
cancer agents vary by more than 50% as a func-
tion of time-of-day dosing in experimental mod-
els. So far there has been no research on the influ-
ence of biological rhythms on the pharmacokinet-
ics of TKI. Due to their wider and wider range of
indications it is important to investigate the most
optimal possibilities of their dosage. If the patient
sleeps during the highest concentrations of the
drug at night, they might not suffer from adverse
reactions resulting from Cmax. On the other hand,
if we achieve high concentrations of TKI in the
blood, the therapy may be improved. This is also
a chance to reduce the dose of the drug.
In our research in the animals which received
the drug in the evening the Cmax and AUC0-t val-
ues of sunitinib were 117.6% and 55.3% higher,
respectively, in comparison with the animals with
the morning administration of the drug. The
higher values of sunitinib AUC in the animals
from group II20:00. prove higher exposure to the
drug. Too high TK concentrations may involve a
higher risk of adverse effects (AEs). The most
frequent AEs of sunitinib are: fatigue, diarrhoea,
hand-foot syndrome and hypertension23. This fact
of higher exposure does not seem to be caused by
slower metabolism. The metabolism of the drug,
including CYP3A4 activity, is controlled by the
circadian timing system22,24,25, but the absence of
statistically significant differences for
SU12662/sunitinib ratios for AUC0-t, AUC0-∞, and
Cmax (Table I) points to the fact that the degree of
metabolism of the drug remained unchanged.
The increase in the concentration of the metabo-
lite is the consequence of the increased concen-
tration of sunitinib.
It is too difficult to give a simple explanation to
significant differences in the drug elimination pa-
under study did not differ significantly in body
mass. There was a wide intersubject variability
in the pharmacokinetic parameters, as evidenced
by the coefficients of variation (CV%) (Table I).
Measurable sunitinib and SU12662 concentra-
tions were achieved within 0.5 and 1 h, respec-
tively, after dosing in all animals and remained
quantifiable at almost all following time points.
Peak sunitinib and SU12662 concentrations were
achieved approximately 6-12 h after dosing. The
arithmetic mean concentrations of sunitinib and
SU12662 in the blood plasma in the different an-
imal groups during 96-h period after administra-
tion of sunitinib are shown in Figures 1 and 2,
respectively.
In the rabbits with administration at 20:00 ele-
vated levels of sunitinib were noted. The mean
Cmax was higher in group II20:00 than in the control
group (240.9 ± 35.3 and 110.7 ± 23.6 ng/mL, re-
spectively; Table I). The comparison of the Cmax
for group II20:00 and the same parameter for group
I08:00 gave a ratio of 2.20 (90% CI 2.17; 2.22).
The mean AUC0-t of sunitinib was not similar for
both groups (5128.4 ± 932.9 and 3301.7 ±
1383.9 ng×h/mL, respectively; Table I). The
comparison of the AUC0-t for group II20:00. and the
same parameter for the control group gave a ratio
of 1.64 (90% CI 1.61; 1.68). There were signifi-
cant differences between the groups under analy-
sis for Cmax and AUC0-t (p < 0.0001 and p =
0.0079, respectively). 
The mean tmax of sunitinib was not similar for
the two groups. The comparison of the difference
for group II20:00 and the same parameter for the
control group gave an estimated decrease in tmax
of 1.0 h (90% CI -3.15; 1.15). There were signif-
icant differences between the groups under
analysis (p = 0.0163).
Statistically significant differences were re-
vealed for elimination half-life (p = 0.0106), and
clearance (p = 0.0151).
There were no significant differences between
the two groups under analysis for the following
pharmacokinetic parameters of SU12662: AUC0-t
(p = 0.0814), AUC0-∞ (p = 0.3979), but there
were significant differences observed for Cmax (p
= 0.0025) and tmax (p = 0.0144).
Also, there were no statistically significant
differences proved for the SU12662/sunitinib ra-
tios for AUC0-t, AUC0-inf, and Cmax (p = 0.8023, p
= 0.1029, p = 0.3992, respectively). 
In all the animals under analysis, a drop in
glucose concentration in the blood was observed.
The reduction in glycemia concentration was
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rameters between the groups under analysis be-
cause of the long drug elimination process, which
takes several days. The shorter t1/2kel and faster
clearance of sunitinib in the group receiving the
drug in the evening may result from the fact that
the beginning of the elimination process (in about
12 h after administration of the drug) takes place
as early as the daytime, which means that the
drug is eliminated more effectively (higher motor
activity, increased flow of blood in the tissues).
This is reflected by the kel(12-24h) value, which is
lower in the control group (0.040 vs. 0.049 h-1),
where the drug is eliminated at nighttime (lower
motor activity, lower flow of blood in the tissues).
The results obtained in many studies26-29 sug-
gest the need to monitor glycaemia frequently
both in diabetic patients and in those with nor-
moglycaemia due to the risk of serious hypogly-
caemia during a sunitinib therapy. In our animals
the mean glycaemia drop was higher in group
I08:00 than in group II20:00 (22.7% vs. 14.3%; p =
0.0622), which may have resulted from the rab-
bits’ increased activity during the day. In our ani-
mals the maximum drop in the concentration of
glucose in the blood was observed about the
sunitinib tmax (6-12 hours). The glycemia values
returned to the initial values in 24 h after the ad-
ministration of sunitinib. It is also known that the
concentration of glucose in the blood is chiefly
regulated by insulin, the secretion of which is
controlled by circadian rhythm. In healthy sub-
jects the peak secretion of insulin in the circadian
rhythm takes place in the afternoon hours. This is
also the time when the concentrations of suni-
tinib were the highest. Therefore, we can suppose
that the hypoglycaemic effect was stronger in the
group of animals receiving sunitinib in the morn-
ing than in those receiving the drug in the
evening. At night the concentration of insulin is
physiologically the lowest. This may account for
the least noticeable changes in the glycaemia val-
ue in the animals from group II20.00. Thus, if the
drug is administered in the evening, the risk of
sunitinib-induced hypoglycemia may be lower
(the tmax of the drug coincides with the physiolog-
ical hyperglycaemia in the morning).
The authors wanted to note that a single check
of glycaemia immediately before administration
of next dose of sunitinib (usually 24 hours after
administration of the drug) may be insufficient. It
suggests the need to check the patient’s glycaemia,
e.g. at lunchtime (when sunitinib is administered
in the morning). Moreover, due to higher concen-
trations of sunitinib at night after the evening ad-
ministration it is necessary to pay attention to the
risk of adverse effects of sunitinib.
Conclusions
The research proved a statistically significant
influence of the time-of-day administration of the
drug on the pharmacokinetics of sunitinib.
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